CClinicalTrials.gg
Sign In
CompletedNCT05808595Updated May 8, 2024

The Safety and Efficacy of AlphaWave® L-Theanine on Adults Who Experience Moderate Stress on a Regular Basis

A Phase 2 interventional study of AlphaWave® L-Theanine and Placebo in Stress, sponsored by Ethical Naturals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Ethical Naturals, Inc. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the efficacy of AlphaWave® L-Theanine on stress among adults who experience moderate stress on a regular basis. The difference in change in stress as assessed by salivary cortisol from baseline at Days 14 and 28 will be compared between AlphaWave® L-Theanine and Placebo groups. Additionally, the safety and tolerability of AlphaWave® L-Theanine, as compared to placebo, will be measured by the occurrence of an/or changes in pre-emergent and post-emergent adverse events (AEs).

02

Conditions studied

  • Stress

Keywords

  • Safety and efficacy
  • Stress
03

In context

Lead sponsor

Ethical Naturals, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Males and females between 18 and 65 years of age, inclusive

  2. Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, total endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,

    Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
  3. Individuals with moderate stress as determined by a score of 14 - 26 on the Perceived Stress Scale
  4. Agrees to maintain current sleep schedule throughout study
  5. Must have a high school diploma or equivalent and basic computer skills
  6. Agrees to avoid high caffeine consumption (examples include but not limited to no more than 2 cups/day of caffeinated coffee or tea)
  7. Agrees to refrain from vigorous physical activity 24-hr prior to study visits
  8. Agrees to maintain current lifestyle as much as possible including current sleep schedule until the end of the study
  9. Willingness to complete questionnaires, records and diaries associated with the study, and to complete all clinic visits
  10. Provided voluntary, written, informed consent to participate in the study
  11. Healthy as determined by medical history, laboratory results, and as assessed by the QI

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  2. Participants who have a known allergy to the Investigational Product (IP) or Placebo active or inactive ingredients
  3. Current employment that calls for rotating shift work or shift work that will disrupt normal circadian rhythm in the last 3 weeks
  4. Travelled across 1 or more time zones in the 3 weeks prior to run-in and/or is anticipating more travel
  5. Self-reported diagnosis with a stress or sleep disorder as assessed by the QI
  6. Self-reported diagnosis of a neuropsychiatric and/or cognitive impairment as assessed by the QI
  7. Self reported colour-blindness
  8. Type I or Type II Diabetes
  9. Unstable metabolic disease or chronic diseases as assessed by the QI
  10. Current or history of any significant disease of the gastrointestinal tract as assessed by the QI
  11. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  12. Significant cardiovascular event in the past 6 months as assessed by the QI
  13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI
  14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  15. Individuals with an autoimmune disease or are immune-compromised
  16. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom-free for 6 months
  17. Self reported current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
  18. Self reported blood/bleeding disorders that will have an effect on safety outcomes as assessed by the QI
  19. Self-reported alcohol or drug abuse within the last 12 months
  20. High alcohol intake (>2 standard drinks per day)
  21. Use of medicinal cannabinoid products, as assessed by the QI
  22. Chronic use of cannabinoid products (≥2 times/week) and is unwilling to stop use for the duration of the study. Occasional use to be assessed by QI on a case-by-case basis
  23. Use of tobacco and nicotine-containing products within 60 days of baseline and during the study period
  24. Current use of prescribed medications which may affect stress, sleep, cognition, and/or mood (see Section 7.3.1)
  25. Current use of over-the-counter medications, supplements, foods, and/or drinks which may affect stress, sleep, cognition, and/or mood unless willing to undergo the appropriate washout (see Section 7.3.2)
  26. Clinically significant abnormal laboratory results at screening as assessed by the QI
  27. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  28. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
  29. Individuals who are unable to give informed consent
  30. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    AlphaWave® L-Theanine

    Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.

    Dietary Supplement: AlphaWave® L-Theanine

  • Placebo comparator
    Placebo

    Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1. If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule. Participants will be advised not to exceed 3 capsules daily.

    Other: Placebo

Interventions

  • Dietary supplementAlphaWave® L-Theanine

    One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.

  • OtherPlacebo

    One capsule of Placebo will be taken twice daily for 28 days.

06

What researchers measure

Primary outcomes

  1. The difference in change in stress as assessed by salivary cortisol from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

Secondary outcomes

  1. The difference in change in stress as measured by the Perceived Stress Scale (PSS) from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

  2. The difference in change in the stress subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

  3. The difference in change in the depression subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

  4. The difference in change in the anxiety subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

  5. The difference in change in the total score measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.

    Time frame: Day 0, day 14, day 28

  6. The difference in change in sleep between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28, as assessed by the Healthy People Sleep Quality Index (HPSQI).

    Time frame: Days 0, 14, and 28

  7. The difference in change in sleep between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28, as assessed by actigraphy readings.

    Actigraphy readings will include data on sleep duration, sleep onset, wake time, sleep latency, sleep efficiency, sleep stages, arousal count, and sleep score (0-100).

    Time frame: Days 0, 14, and 28

  8. The difference in change in cognition between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28.

    The difference in change in cognition will be assessed by the Computerized Mental Performance Assessment System (COMPASS): Stroop Test, Simple Reaction Time, and Choice Reaction Time.

    Time frame: Days 0, 14, and 28

  9. The difference in change in mood between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28.

    The difference in change in mood will be assessed by the Profile of Mood States (POMS) questionnaire.

    Time frame: Days 0, 14, and 28

  10. Incidence of pre-emergent and post-emergent adverse events (AE) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: 28 days

  11. Measurement of blood pressure (BP) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 0, day 14, day 28

  12. Measurement of heart rate (HR) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 0, day 14, day 28

  13. Measurement of aspartate aminotransferase (AST) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  14. Measurement of alanine aminotransferase (ALT) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  15. Measurement of alkaline phosphatase (ALP) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  16. Measurement of total bilirubin following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  17. Measurement of creatinine following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  18. Measurement of electrolytes following supplementation with AlphaWave® L-Theanine and Placebo.

    Electrolytes to be measured include sodium, potassium, and chloride.

    Time frame: screening, day 28

  19. Measurement of glucose following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  20. Measurement of estimated glomerular filtration rate (eGFR) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  21. Measurement of white blood cell count (WBC) with differential following supplementation with AlphaWave® L-Theanine and Placebo.

    WBC differentials include neutrophils, lymphocytes, monocytes, eosinophils, and basophils.

    Time frame: screening, day 28

  22. Measurement of red blood cell count (RBC) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  23. Measurement of hemoglobin following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  24. Measurement of hematocrit following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  25. Measurement of platelet count following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  26. Measurement of immature granulocytes following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  27. Measurement of nucleated red blood cells (RBC) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  28. Measurement of mean corpuscular volume (MCV) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  29. Measurement of mean corpuscular hemoglobin (MCH) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  30. Measurement of mean corpuscular hemoglobin concentration (MCHC) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

  31. Measurement of red blood cell distribution width (RDW) following supplementation with AlphaWave® L-Theanine and Placebo.

    Time frame: screening, day 28

07

Study locations

1 site
  • KGK Science Inc.
    London, Ontario N6B 3L1, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05808595
Lead sponsor
Ethical Naturals, Inc.
Collaborators
KGK Science Inc.
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Apr 4, 2023
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023
Last update
May 8, 2024

Study contacts

David Crowley, MD
principal investigator · KGK Science Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Ethical Naturals, Inc.

Start the discussion